Skip to main content

For US Healthcare Professionals

CIMERLI® patient and provider support

Sandoz One Source® helps ease administrative burdens and streamlines patient access

Find a simplified suite of patient assistance, industry-leading electronic services, and office support to ensure successful access and reimbursement.

Access the Sandoz One Source Provider Portal (opens in a new tab)

Comprehensive reimbursement services to support your practice

Sandoz One Source offers reimbursement solutions you can count on:

Benefit Verification Support

Determine treatment coverage through electronic medical benefit verification

Prior Authorization Support

Ease administration burden with support for required prior authorizations or predeterminations*

Coding and Billing Support

Sample coding and billing information is available to help facilitate appropriate claims submission†

Patient Financial Assistance

CIMERLI® may be available to your patients at no cost‡

Appeals Assistance

Resources to help you confirm the medical necessity of CIMERLI® and appeal denied claims§

Product Replacement

Assistance with product replacement

Download the CIMERLI®
Coding Flashcard (opens in a new tab)

*If your patient's request for required authorizations isn't granted, your field reimbursement manager can work with you to determine next steps.

†Correct coding is the responsibility of the provider submitting the claim for the item or service. Please check with the payer to verify codes and special billing requirements. Sandoz One Source does not make any representation or guarantee concerning reimbursement or coverage for any service or item.

‡Eligibility requirements, type of assistance, and application process varies.

§Sandoz One Source cannot complete or submit appeals on your behalf.

State-specific coverage information

Visit the Payer Coverage Center

CO-PAY SAVINGS PROGRAM

Your patients may pay as little as $0 for CIMERLI®

The Co-Pay Savings Program may cover out-of-pocket costs associated with CIMERLI® and the injection procedure for eligible patients with commercial insurance.*

Icon: Pay as little as $0

per dose of CIMERLI® including injection

Maximum annual benefit of $16,000
per calendar year.

*Drug and Injection Co-Pay Eligibility Criteria:

  • Be prescribed CIMERLI® for a medically appropriate purpose consistent with its FDA-approved labeling within 180 days of program enrollment
  • Have commercial (private or non-governmental) health insurance that covers the medication costs of CIMERLI®
  • Not covered by any federal, state, or government-funded healthcare program, such as Medicare, Medicare Advantage, Medicare Part D, Veterans Affairs, Department of Defense, or TRICARE
  • Not seek reimbursement from any third party, including payers, charitable foundations, or flexible spending account (FSAs) or healthcare savings accounts (HSAs) for all or any part of the benefit received by Sandoz through this program
  • Other restrictions apply, see Terms & Conditions (opens in a new tab)
  • It is not valid for cash-paying patients or where prohibited by law
  • CIMERLI® co-pay program subject to change or discontinuation without notice. This is not health insurance

Financial assistance for greater patient access to quality treatment

Whether your patients are commercially insured, uninsured, underinsured, or on Medicare, Sandoz One Source has assistance programs that may help ease payment concerns.

SANDOZ PATIENT ASSISTANCE (SPA)

Uninsured or underinsured patients may receive CIMERLI® at no cost§

Sandoz Patient Assistance (SPA) is committed to providing access to Sandoz medications for those most in need. If your patient is experiencing financial hardship, cannot afford the cost of treatment, and has limited or no prescription coverage, then your patient may be eligible to receive Sandoz medications for free.

To be eligible for SPA assistance, your patient must:

  • Reside in the United States or a U.S. Territory
  • Have limited or no prescription insurance coverage
  • Meet income guidelines adjusted for household size, for the medication for which the patient is seeking assistance
  • Have a valid prescription for the Sandoz medication
  • Be treated by a licensed U.S. healthcare provider
  • Complete and sign consent form and, when applicable, provide income documentation

§To be considered functionally underinsured, the patient does not have coverage for CIMERLI® or any other anti-VEGF or ranibizumab product.

Independent co-pay foundations

Assistance with out-of-pocket costs

Charitable organizations may be able to provide financial assistance if your patients have commercial insurance or government insurance, including Medicare and Medicaid.‖

Your patient can contact these independent foundations directly or a Sandoz One Source® specialist can help determine if they are eligible at 1-844-4SANDOZ (1-844-472-6369).

‖Independent foundations have their own rules for eligibility. Sandoz has no involvement or influence in independent foundation decision-making or eligibility criteria.

3 ways to connect with Sandoz One Source

Computer Icon

Visit Sandoz One Source (opens in a new tab) to enroll for comprehensive reimbursement support

Calling Icon

Call 1-844-4SANDOZ (1-844-472-6369) for reimbursement inquiries

Text Bubbles Icon

Contact your field reimbursement manager for patient access and reimbursement education and complex support issues

Access the Sandoz One Source Provider Portal (opens in a new tab)

CIMERLI® was proven clinically equivalent to Lucentis® (ranibizumab injection) in terms of efficacy and safety1

See head-to-head data

Request a visit from a Sandoz representative

Connect with us

Important Safety Information

Important Safety Information

CONTRAINDICATIONS: CIMERLI® (ranibizumab-eqrn) is contraindicated in patients with ocular or periocular infections or known hypersensitivity to ranibizumab products or any of the excipients in CIMERLI®. Hypersensitivity reactions may manifest as severe intraocular inflammation.

WARNINGS AND PRECAUTIONS

  • Endophthalmitis and Retinal Detachments: Intravitreal injections, including those with ranibizumab products, have been associated with endophthalmitis, retinal detachment, and iatrogenic traumatic cataract. Proper aseptic injection technique should always be utilized when administering CIMERLI®. In addition, patients should be monitored following the injection to permit early treatment, should an infection occur
  • Increases in Intraocular Pressure: Increases in intraocular pressure have been noted both pre-injection and post-injection (at 60 minutes) while being treated with ranibizumab products. Monitor intraocular pressure prior to and following intravitreal injection with CIMERLI® and manage appropriately
  • Thromboembolic Events: Although there was a low rate of arterial thromboembolic events (ATEs) observed in the ranibizumab clinical trials, there is a potential risk of ATEs following intravitreal use of VEGF inhibitors. ATEs are defined as nonfatal stroke, nonfatal myocardial infarction, or vascular death (including deaths of unknown cause)

Neovascular (Wet) Age-Related Macular Degeneration (wAMD)

  • The ATE rate in the three controlled neovascular AMD studies (AMD-1, AMD-2, AMD-3) during the first year was 1.9% (17 of 874) in the combined group of patients treated with 0.3 mg or 0.5 mg ranibizumab compared with 1.1% (5 of 441) in patients from the control arms. In the second year of Studies AMD-1 and AMD-2, the ATE rate was 2.6% (19 of 721) in the combined group of ranibizumab-treated patients compared with 2.9% (10 of 344) in patients from the control arms. In Study AMD-4, the ATE rates observed in the 0.5 mg arms during the first and second year were similar to rates observed in Studies AMD-1, AMD-2, and AMD-3
  • In a pooled analysis of 2-year controlled studies (AMD-1, AMD-2, and a study of ranibizumab used adjunctively with verteporfin photodynamic therapy), the stroke rate (including both ischemic and hemorrhagic stroke) was 2.7% (13 of 484) in patients treated with 0.5 mg ranibizumab compared to 1.1% (5 of 435) in patients in the control arms (odds ratio 2.2 [95% confidence interval (0.8-7.1)])

Macular Edema Following Retinal Vein Occlusion (RVO)

  • The ATE rate in the two controlled RVO studies during the first 6 months was 0.8% in both the ranibizumab and control arms of the studies (4 of 525 in the combined group of patients treated with 0.3 mg or 0.5 mg ranibizumab and 2 of 260 in the control arms). The stroke rate was 0.2% (1 of 525) in the combined group of ranibizumab-treated patients compared to 0.4% (1 of 260) in the control arms

Diabetic Macular Edema (DME) and Diabetic Retinopathy (DR)

  • In a pooled analysis of Studies D-1 and D-2, the ATE rate at 2 years was 7.2% (18 of 250) with 0.5 mg ranibizumab, 5.6% (14 of 250) with 0.3 mg ranibizumab, and 5.2% (13 of 250) with control. The stroke rate at 2 years was 3.2% (8 of 250) with 0.5 mg ranibizumab, 1.2% (3 of 250) with 0.3 mg ranibizumab, and 1.6% (4 of 250) with control. At 3 years, the ATE rate was 10.4% (26 of 249) with 0.5 mg ranibizumab and 10.8% (27 of 250) with 0.3 mg ranibizumab; the stroke rate was 4.8% (12 of 249) with 0.5 mg ranibizumab and 2.0% (5 of 250) with 0.3 mg ranibizumab
  • Fatal events occurred more frequently in patients with DME and DR at baseline: A pooled analysis of Studies D-1 and D-2 showed that fatalities in the first 2 years occurred in 4.4% (11 of 250) of patients treated with 0.5 mg ranibizumab, in 2.8% (7 of 250) of patients treated with 0.3 mg ranibizumab, and in 1.2% (3 of 250) of control patients. Over 3 years, fatalities occurred in 6.4% (16 of 249) of patients treated with 0.5 mg ranibizumab and in 4.4% (11 of 250) of patients treated with 0.3 mg ranibizumab. Although the rate of fatal events was low and included causes of death typical of patients with advanced diabetic complications, a potential relationship between these events and intravitreal use of VEGF inhibitors cannot be excluded
  • Retinal vasculitis with or without occlusion, typically in the presence of preexisting intraocular inflammation or post-treatment with other intravitreal agents, have been reported with the use of ranibizumab products. Discontinue treatment with CIMERLI® in patients who develop these events. Patients should be instructed to report any change in vision without delay

ADVERSE REACTIONS

  • Serious adverse reactions related to the injection procedure that occurred in <0.1% of intravitreal injections, including endophthalmitis, rhegmatogenous retinal detachment, and iatrogenic traumatic cataract
  • The most frequently reported ocular adverse reactions in ranibizumab-treated patients compared with the control group were conjunctival hemorrhage, eye pain, vitreous floaters, and increased intraocular pressure. The most common non-ocular adverse reactions were nasopharyngitis, anemia, nausea, and cough
  • As with all therapeutic proteins, there is the potential for an immune response in patients treated with ranibizumab products. The clinical significance of immunoreactivity to ranibizumab products is unclear at this time

Postmarketing Experience

The following adverse reaction has been identified during post-approval use of ranibizumab products:

  • Ocular: Tear of retinal pigment epithelium among patients with neovascular AMD

To report SUSPECTED ADVERSE REACTIONS, contact Sandoz, Inc at 1-800-525-8747 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch (opens in a new tab).

Before prescribing, please see CIMERLI® Prescribing Information (opens in a new tab).

Indications

Indications

CIMERLI® is indicated for the treatment of patients with:

  • Neovascular (wet) Age-Related Macular Degeneration (wAMD)
  • Macular Edema Following Retinal Vein Occlusion (RVO)
  • Diabetic Macular Edema (DME)
  • Diabetic Retinopathy (DR)
  • Myopic Choroidal Neovascularization (mCNV)

Reference:

  1. Holz FG, Oleksy P, Ricci F, et al. Efficacy and Safety of Biosimilar FYB201 Compared with Ranibizumab in Neovascular Age-Related Macular Degeneration. Ophthalmology. 2022;129(1):54-63. doi:10.1016/j.ophtha.2021.04.031

Important Safety Information

Important Safety Information

CONTRAINDICATIONS: CIMERLI® (ranibizumab-eqrn) is contraindicated in patients with ocular or periocular infections or known hypersensitivity to ranibizumab products or any of the excipients in CIMERLI®. Hypersensitivity reactions may manifest as severe intraocular inflammation.

WARNINGS AND PRECAUTIONS

  • Endophthalmitis and Retinal Detachments: Intravitreal injections, including those with ranibizumab products, have been associated with endophthalmitis, retinal detachment, and iatrogenic traumatic cataract. Proper aseptic injection technique should always be utilized when administering CIMERLI®. In addition, patients should be monitored following the injection to permit early treatment, should an infection occur
  • Increases in Intraocular Pressure: Increases in intraocular pressure have been noted both pre-injection and post-injection (at 60 minutes) while being treated with ranibizumab products. Monitor intraocular pressure prior to and following intravitreal injection with CIMERLI® and manage appropriately
  • Thromboembolic Events: Although there was a low rate of arterial thromboembolic events (ATEs) observed in the ranibizumab clinical trials, there is a potential risk of ATEs following intravitreal use of VEGF inhibitors. ATEs are defined as nonfatal stroke, nonfatal myocardial infarction, or vascular death (including deaths of unknown cause)

Neovascular (Wet) Age-Related Macular Degeneration (wAMD)

  • The ATE rate in the three controlled neovascular AMD studies (AMD-1, AMD-2, AMD-3) during the first year was 1.9% (17 of 874) in the combined group of patients treated with 0.3 mg or 0.5 mg ranibizumab compared with 1.1% (5 of 441) in patients from the control arms. In the second year of Studies AMD-1 and AMD-2, the ATE rate was 2.6% (19 of 721) in the combined group of ranibizumab-treated patients compared with 2.9% (10 of 344) in patients from the control arms. In Study AMD-4, the ATE rates observed in the 0.5 mg arms during the first and second year were similar to rates observed in Studies AMD-1, AMD-2, and AMD-3
  • In a pooled analysis of 2-year controlled studies (AMD-1, AMD-2, and a study of ranibizumab used adjunctively with verteporfin photodynamic therapy), the stroke rate (including both ischemic and hemorrhagic stroke) was 2.7% (13 of 484) in patients treated with 0.5 mg ranibizumab compared to 1.1% (5 of 435) in patients in the control arms (odds ratio 2.2 [95% confidence interval (0.8-7.1)])

Macular Edema Following Retinal Vein Occlusion (RVO)

  • The ATE rate in the two controlled RVO studies during the first 6 months was 0.8% in both the ranibizumab and control arms of the studies (4 of 525 in the combined group of patients treated with 0.3 mg or 0.5 mg ranibizumab and 2 of 260 in the control arms). The stroke rate was 0.2% (1 of 525) in the combined group of ranibizumab-treated patients compared to 0.4% (1 of 260) in the control arms

Diabetic Macular Edema (DME) and Diabetic Retinopathy (DR)

  • In a pooled analysis of Studies D-1 and D-2, the ATE rate at 2 years was 7.2% (18 of 250) with 0.5 mg ranibizumab, 5.6% (14 of 250) with 0.3 mg ranibizumab, and 5.2% (13 of 250) with control. The stroke rate at 2 years was 3.2% (8 of 250) with 0.5 mg ranibizumab, 1.2% (3 of 250) with 0.3 mg ranibizumab, and 1.6% (4 of 250) with control. At 3 years, the ATE rate was 10.4% (26 of 249) with 0.5 mg ranibizumab and 10.8% (27 of 250) with 0.3 mg ranibizumab; the stroke rate was 4.8% (12 of 249) with 0.5 mg ranibizumab and 2.0% (5 of 250) with 0.3 mg ranibizumab
  • Fatal events occurred more frequently in patients with DME and DR at baseline: A pooled analysis of Studies D-1 and D-2 showed that fatalities in the first 2 years occurred in 4.4% (11 of 250) of patients treated with 0.5 mg ranibizumab, in 2.8% (7 of 250) of patients treated with 0.3 mg ranibizumab, and in 1.2% (3 of 250) of control patients. Over 3 years, fatalities occurred in 6.4% (16 of 249) of patients treated with 0.5 mg ranibizumab and in 4.4% (11 of 250) of patients treated with 0.3 mg ranibizumab. Although the rate of fatal events was low and included causes of death typical of patients with advanced diabetic complications, a potential relationship between these events and intravitreal use of VEGF inhibitors cannot be excluded
  • Retinal vasculitis with or without occlusion, typically in the presence of preexisting intraocular inflammation or post-treatment with other intravitreal agents, have been reported with the use of ranibizumab products. Discontinue treatment with CIMERLI® in patients who develop these events. Patients should be instructed to report any change in vision without delay

ADVERSE REACTIONS

  • Serious adverse reactions related to the injection procedure that occurred in <0.1% of intravitreal injections, including endophthalmitis, rhegmatogenous retinal detachment, and iatrogenic traumatic cataract
  • The most frequently reported ocular adverse reactions in ranibizumab-treated patients compared with the control group were conjunctival hemorrhage, eye pain, vitreous floaters, and increased intraocular pressure. The most common non-ocular adverse reactions were nasopharyngitis, anemia, nausea, and cough
  • As with all therapeutic proteins, there is the potential for an immune response in patients treated with ranibizumab products. The clinical significance of immunoreactivity to ranibizumab products is unclear at this time

Postmarketing Experience

The following adverse reaction has been identified during post-approval use of ranibizumab products:

  • Ocular: Tear of retinal pigment epithelium among patients with neovascular AMD

To report SUSPECTED ADVERSE REACTIONS, contact Sandoz, Inc at 1-800-525-8747 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch (opens in a new tab).

Before prescribing, please see CIMERLI® Prescribing Information (opens in a new tab).

Indications

Indications

CIMERLI® is indicated for the treatment of patients with:

  • Neovascular (wet) Age-Related Macular Degeneration (wAMD)
  • Macular Edema Following Retinal Vein Occlusion (RVO)
  • Diabetic Macular Edema (DME)
  • Diabetic Retinopathy (DR)
  • Myopic Choroidal Neovascularization (mCNV)

Important Safety Information

CONTRAINDICATIONS: CIMERLI® (ranibizumab-eqrn) is contraindicated in patients with ocular or periocular infections or known hypersensitivity to ranibizumab products or any of the excipients in CIMERLI®. Hypersensitivity reactions may manifest as severe intraocular inflammation.

Important Safety Information

Important Safety Information

CONTRAINDICATIONS: CIMERLI® (ranibizumab-eqrn) is contraindicated in patients with ocular or periocular infections or known hypersensitivity to ranibizumab products or any of the excipients in CIMERLI®. Hypersensitivity reactions may manifest as severe intraocular inflammation.

WARNINGS AND PRECAUTIONS

  • Endophthalmitis and Retinal Detachments: Intravitreal injections, including those with ranibizumab products, have been associated with endophthalmitis, retinal detachment, and iatrogenic traumatic cataract. Proper aseptic injection technique should always be utilized when administering CIMERLI®. In addition, patients should be monitored following the injection to permit early treatment, should an infection occur
  • Increases in Intraocular Pressure: Increases in intraocular pressure have been noted both pre-injection and post-injection (at 60 minutes) while being treated with ranibizumab products. Monitor intraocular pressure prior to and following intravitreal injection with CIMERLI® and manage appropriately
  • Thromboembolic Events: Although there was a low rate of arterial thromboembolic events (ATEs) observed in the ranibizumab clinical trials, there is a potential risk of ATEs following intravitreal use of VEGF inhibitors. ATEs are defined as nonfatal stroke, nonfatal myocardial infarction, or vascular death (including deaths of unknown cause)

Neovascular (Wet) Age-Related Macular Degeneration (wAMD)

  • The ATE rate in the three controlled neovascular AMD studies (AMD-1, AMD-2, AMD-3) during the first year was 1.9% (17 of 874) in the combined group of patients treated with 0.3 mg or 0.5 mg ranibizumab compared with 1.1% (5 of 441) in patients from the control arms. In the second year of Studies AMD-1 and AMD-2, the ATE rate was 2.6% (19 of 721) in the combined group of ranibizumab-treated patients compared with 2.9% (10 of 344) in patients from the control arms. In Study AMD-4, the ATE rates observed in the 0.5 mg arms during the first and second year were similar to rates observed in Studies AMD-1, AMD-2, and AMD-3
  • In a pooled analysis of 2-year controlled studies (AMD-1, AMD-2, and a study of ranibizumab used adjunctively with verteporfin photodynamic therapy), the stroke rate (including both ischemic and hemorrhagic stroke) was 2.7% (13 of 484) in patients treated with 0.5 mg ranibizumab compared to 1.1% (5 of 435) in patients in the control arms (odds ratio 2.2 [95% confidence interval (0.8-7.1)])

Macular Edema Following Retinal Vein Occlusion (RVO)

  • The ATE rate in the two controlled RVO studies during the first 6 months was 0.8% in both the ranibizumab and control arms of the studies (4 of 525 in the combined group of patients treated with 0.3 mg or 0.5 mg ranibizumab and 2 of 260 in the control arms). The stroke rate was 0.2% (1 of 525) in the combined group of ranibizumab-treated patients compared to 0.4% (1 of 260) in the control arms

Diabetic Macular Edema (DME) and Diabetic Retinopathy (DR)

  • In a pooled analysis of Studies D-1 and D-2, the ATE rate at 2 years was 7.2% (18 of 250) with 0.5 mg ranibizumab, 5.6% (14 of 250) with 0.3 mg ranibizumab, and 5.2% (13 of 250) with control. The stroke rate at 2 years was 3.2% (8 of 250) with 0.5 mg ranibizumab, 1.2% (3 of 250) with 0.3 mg ranibizumab, and 1.6% (4 of 250) with control. At 3 years, the ATE rate was 10.4% (26 of 249) with 0.5 mg ranibizumab and 10.8% (27 of 250) with 0.3 mg ranibizumab; the stroke rate was 4.8% (12 of 249) with 0.5 mg ranibizumab and 2.0% (5 of 250) with 0.3 mg ranibizumab
  • Fatal events occurred more frequently in patients with DME and DR at baseline: A pooled analysis of Studies D-1 and D-2 showed that fatalities in the first 2 years occurred in 4.4% (11 of 250) of patients treated with 0.5 mg ranibizumab, in 2.8% (7 of 250) of patients treated with 0.3 mg ranibizumab, and in 1.2% (3 of 250) of control patients. Over 3 years, fatalities occurred in 6.4% (16 of 249) of patients treated with 0.5 mg ranibizumab and in 4.4% (11 of 250) of patients treated with 0.3 mg ranibizumab. Although the rate of fatal events was low and included causes of death typical of patients with advanced diabetic complications, a potential relationship between these events and intravitreal use of VEGF inhibitors cannot be excluded
  • Retinal vasculitis with or without occlusion, typically in the presence of preexisting intraocular inflammation or post-treatment with other intravitreal agents, have been reported with the use of ranibizumab products. Discontinue treatment with CIMERLI® in patients who develop these events. Patients should be instructed to report any change in vision without delay

ADVERSE REACTIONS

  • Serious adverse reactions related to the injection procedure that occurred in <0.1% of intravitreal injections, including endophthalmitis, rhegmatogenous retinal detachment, and iatrogenic traumatic cataract
  • The most frequently reported ocular adverse reactions in ranibizumab-treated patients compared with the control group were conjunctival hemorrhage, eye pain, vitreous floaters, and increased intraocular pressure. The most common non-ocular adverse reactions were nasopharyngitis, anemia, nausea, and cough
  • As with all therapeutic proteins, there is the potential for an immune response in patients treated with ranibizumab products. The clinical significance of immunoreactivity to ranibizumab products is unclear at this time

Postmarketing Experience

The following adverse reaction has been identified during post-approval use of ranibizumab products:

  • Ocular: Tear of retinal pigment epithelium among patients with neovascular AMD

To report SUSPECTED ADVERSE REACTIONS, contact Sandoz, Inc at 1-800-525-8747 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch (opens in a new tab).

Before prescribing, please see CIMERLI® Prescribing Information (opens in a new tab).

Indications

CIMERLI® is indicated for the treatment of patients with:

  • Neovascular (wet) age-related macular degeneration (wAMD)
  • Macular Edema Following Retinal Vein Occlusion (RVO)

Indications

Indications

Indications

CIMERLI® is indicated for the treatment of patients with:

  • Neovascular (wet) Age-Related Macular Degeneration (wAMD)
  • Macular Edema Following Retinal Vein Occlusion (RVO)
  • Diabetic Macular Edema (DME)
  • Diabetic Retinopathy (DR)
  • Myopic Choroidal Neovascularization (mCNV)

You are now
leaving CIMERLI.com

Sandoz is not responsible for the content of linked third-party websites. Please be aware that the privacy policies and terms of use on these sites are different from Sandoz policies.

Cancel Leave Site (opens in a new tab)

Please select which best describes you:

Healthcare Professional Patient or Caregiver